Launch of new lyme test products for the european market
| Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, has announced the launch of its new Lyme Enzyme Immunoassay (EIA) products specifically designed for the European market. |
The new products, the Trinity Biotech EU Lyme IgG + VlsE EIA and the EU Lyme IgM EIA are designed for use as screening assays in clinical laboratories. They are qualitative serological tests for the detection of IgG and IgM antibodies to the most prevalent and clinically important Borrelia species in Europe, i.e. Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi. The addition of VlsE to the product significantly boosts sensitivity of the assay. These new products complete Trinity Biotechs product offering for Lyme Disease in Europe, complementing the existing EU Lyme Western Blot confirmatory assays.
Borrelia species cause Lyme Disease in humans following transmission via a tick bite. Lyme Disease is the most common tick-borne disease in the EU. The most frequent symptoms include skin rash, diffuse flu-like reaction and joint pains. The characteristic rash is not always present making diagnosis more difficult. If untreated or inadequately treated, neurological, cardiac, or serious joint abnormalities may follow. Eurosurveillance reports that the incidence of Lyme Disease is on the increase across Europe with particularly high increases seen in Northern and Eastern Europe.
The continued expansion of this market segment is driven by factors that increase exposure to ticks. Greater participation in outdoor activities such as hiking, hunting and fishing and recent milder winters have contributed to the proliferation of tick numbers with a consequent increased incidence of Lyme Disease.
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Trinity Biotech Plc View archived contact details
Posted on January 28, 2008